GLPwatch
Xultophy for Cardiovascular risk reduction
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for reducing cardiovascular risk. Research in animal and cell studies suggests potential cardiovascular benefits, but human clinical outcomes are not established in this context.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Xultophy is not FDA-approved for cardiovascular risk reduction; the research below reflects investigational or off-label study only.
Research on liraglutide for cardiovascular risk reduction (50)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- The Discovery and Development of Liraglutide and Semaglutide.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension.
- Liraglutide causes large and rapid epicardial fat reduction.
- Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
- Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
- A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells.
- Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
- Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
- Liraglutide.
- Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
- A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
- Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
- Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
- Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study.